RT @BenjaminKearns2: Very good paper by @NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results t…
Cure models seem to be the way forward for extrapolating survival from PD1 inhibitors https://t.co/73agQVifw8
RT @BenjaminKearns2: Very good paper by @NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results t…
RT @BenjaminKearns2: Very good paper by @NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results t…
RT @BenjaminKearns2: Very good paper by @NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results t…
ScHARRSheffield: RT BenjaminKearns2: Very good paper by NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results to model choice, and the difficulty in identifying the 'best' model for extrapolation. https://t.co/Avp
ScHARRSheffield: RT BenjaminKearns2: Very good paper by NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results to model choice, and the difficulty in identifying the 'best' model for extrapolation. https://t.co/Yov
RT @BenjaminKearns2: Very good paper by @NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results t…
ScHARRHEDS: RT BenjaminKearns2: Very good paper by NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results to model choice, and the difficulty in identifying the 'best' model for extrapolation. https://t.co/2BaJHWrJ
ScHARRHEDS: RT BenjaminKearns2: Very good paper by NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results to model choice, and the difficulty in identifying the 'best' model for extrapolation. https://t.co/YovRqDWi
ScHARRHEDS: RT BenjaminKearns2: Very good paper by NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results to model choice, and the difficulty in identifying the 'best' model for extrapolation. https://t.co/AvpbqsSf
RT @BenjaminKearns2: Very good paper by @NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results t…
RT @BenjaminKearns2: Very good paper by @NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results t…
RT @BenjaminKearns2: Very good paper by @NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results t…
RT @BenjaminKearns2: Very good paper by @NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results t…
RT @BenjaminKearns2: Very good paper by @NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results t…
RT @BenjaminKearns2: Very good paper by @NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results t…
RT @BenjaminKearns2: Very good paper by @NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results t…
Very good paper by @NRLatimer and colleagues on extrapolating survival data in HTA. Shows the sensitivity of results to model choice, and the difficulty in identifying the 'best' model for extrapolation. https://t.co/M7vIKQltPe
RT @PECjournal: Estimating survival in patients treated with immunotherapies @HEvigilante @NRLatimer et al. https://t.co/3KmrjTJIZo
RT @PECjournal: Estimating survival in patients treated with immunotherapies @HEvigilante @NRLatimer et al. https://t.co/3KmrjTJIZo
RT @PECjournal: Estimating survival in patients treated with immunotherapies @HEvigilante @NRLatimer et al. https://t.co/3KmrjTJIZo
RT @PECjournal: Estimating survival in patients treated with immunotherapies @HEvigilante @NRLatimer et al. https://t.co/3KmrjTJIZo
RT @PECjournal: Estimating survival in patients treated with immunotherapies @HEvigilante @NRLatimer et al. https://t.co/3KmrjTJIZo
Estimating survival in patients treated with immunotherapies @HEvigilante @NRLatimer et al. https://t.co/3KmrjTJIZo
#HealthEconJA Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations https://t.co/Ia2Amn06LE